NeoPharm Valuation
| 092730 Stock | KRW 11,520 40.00 0.35% |
At this time, the firm appears to be overvalued. NeoPharm LTD secures a last-minute Real Value of W9530.48 per share. The latest price of the firm is W11520.0. Our model forecasts the value of NeoPharm LTD from analyzing the firm fundamentals such as Return On Equity of 13.82, current valuation of 153.58 B, and Profit Margin of 0.21 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that NeoPharm's price fluctuation is very steady at this time. Calculation of the real value of NeoPharm LTD is based on 3 months time horizon. Increasing NeoPharm's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since NeoPharm is currently traded on the exchange, buyers and sellers on that exchange determine the market value of NeoPharm Stock. However, NeoPharm's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 11520.0 | Real 9530.48 | Hype 11520.0 | Naive 11151.11 |
The real value of NeoPharm Stock, also known as its intrinsic value, is the underlying worth of NeoPharm LTD Company, which is reflected in its stock price. It is based on NeoPharm's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of NeoPharm's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of NeoPharm LTD helps investors to forecast how NeoPharm stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of NeoPharm more accurately as focusing exclusively on NeoPharm's fundamentals will not take into account other important factors: NeoPharm Total Value Analysis
NeoPharm LTD is presently forecasted to have takeover price of 153.58 B with market capitalization of 156.02 B, debt of 101.79 M, and cash on hands of 7.05 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the NeoPharm fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
153.58 B | 156.02 B | 101.79 M | 7.05 B |
NeoPharm Investor Information
About 39.0% of the company shares are owned by insiders or employees . The company recorded earning per share (EPS) of 576.0. NeoPharm LTD had not issued any dividends in recent years. The entity had 1:2 split on the 30th of October 2024. NeoPharm LTD is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.NeoPharm Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. NeoPharm has an asset utilization ratio of 61.32 percent. This suggests that the Company is making W0.61 for each dollar of assets. An increasing asset utilization means that NeoPharm LTD is more efficient with each dollar of assets it utilizes for everyday operations.NeoPharm Ownership Allocation
The market capitalization of NeoPharm LTD is W156.02 Billion. NeoPharm LTD holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please take into account that even companies with profitable outlook can generate negative future returns on their equity. If the true value of the firm is less than the current market value, you may not be able generate positive returns on investment in the long run.NeoPharm Profitability Analysis
The company reported the revenue of 87.93 B. Net Income was 17.71 B with profit before overhead, payroll, taxes, and interest of 58.64 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates NeoPharm's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in NeoPharm and how it compares across the competition.
About NeoPharm Valuation
The stock valuation mechanism determines NeoPharm's current worth on a weekly basis. Our valuation model uses a comparative analysis of NeoPharm. We calculate exposure to NeoPharm's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of NeoPharm's related companies.,Ltd. manufactures and sells skin care products in Korea and internationally. ,Ltd. was founded in 2000 and is headquartered in Daejeon, South Korea. Neopharm is traded on Korean Securities Dealers Automated Quotations in South Korea.
8 Steps to conduct NeoPharm's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates NeoPharm's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct NeoPharm's valuation analysis, follow these 8 steps:- Gather financial information: Obtain NeoPharm's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine NeoPharm's revenue streams: Identify NeoPharm's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research NeoPharm's industry and market trends, including the size of the market, growth rate, and competition.
- Establish NeoPharm's growth potential: Evaluate NeoPharm's management, business model, and growth potential.
- Determine NeoPharm's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate NeoPharm's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for NeoPharm Stock analysis
When running NeoPharm's price analysis, check to measure NeoPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeoPharm is operating at the current time. Most of NeoPharm's value examination focuses on studying past and present price action to predict the probability of NeoPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeoPharm's price. Additionally, you may evaluate how the addition of NeoPharm to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |